Hennion & Walsh Asset Management’s Aldeyra Therapeutics ALDX Stock Holding History

Hennion & Walsh Asset Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-69,442	Closed	-$399K	–	919
2025 Q1	$399K	Sell	69,442 -16,006	-19%	-$94.6K	0.02%	697
2024 Q4	$426K	Sell	85,448 -1,588	-2%	-$8.15K	0.02%	663
2024 Q3	$469K	Sell	87,036 -1,086	-1%	-$5.17K	0.02%	635
2024 Q2	$292K	Buy	88,122 +6,944	+9%	+$27.2K	0.02%	735
2024 Q1	$265K	Buy	81,178 +1,977	+2%	+$6.5K	0.01%	732
2023 Q4	$278K	Buy	79,201 +5,532	+8%	+$17.1K	0.02%	700
2023 Q3	$492K	Buy	73,669 +34,796	+90%	+$258K	0.03%	524
2023 Q2	$326K	Buy	+38,873	New	+$383K	0.02%	631

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hennion & Walsh Asset Management's ALDX Position: Q2 2025 in Review

Hennion & Walsh Asset Management sold out of Aldeyra Therapeutics (ALDX) in Q2 2025, closing a stake of 69,442 shares — an estimated $399K sold.

Hennion & Walsh Asset Management first reported a position in ALDX in Q2 2023 and held it in 8 quarters. The position peaked at $492K in Q3 2023. 121 funds tracked by Wall St. Rank hold ALDX as of Q2 2025.

Hennion & Walsh Asset Management reported no remaining Aldeyra Therapeutics position as of Q2 2025 after selling out during the quarter.
Hennion & Walsh Asset Management sold 69,442 Aldeyra Therapeutics shares in Q2 2025, an estimated $399K.
Hennion & Walsh Asset Management first reported a position in Aldeyra Therapeutics in Q2 2023 and held it in 8 quarters.
Hennion & Walsh Asset Management's Aldeyra Therapeutics position peaked at $492K in Q3 2023.
121 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2025.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.